3 Penny Stocks With Revenue Growth Over 1%

Bond yields are surging worldwide and the era of easy money has faded, which puts a harsh spotlight on fragile balance sheets. Bigger companies can often refinance or cut costs. Smaller stocks trading under US$5 do not always have that luxury. That is where financially solid low priced shares become interesting. This article highlights three financially grounded penny stocks that screen for stronger balance sheets and cleaner funding profiles.

The three stocks covered next are just a sample of what financially stronger, low-priced shares can look like. The full screen surfaced 316 more companies with similarly robust stories that are not included here.

If you want to identify, filter and analyze that wider pool of ideas with a single tool, head straight to the Financially Fit Penny Stocks screener.

Nuvation Bio (NUVB)

Overview: Nuvation Bio is a clinical-stage oncology company developing targeted cancer therapies, led by IBTROZI for ROS1+ lung cancer and safusidenib for IDH1-mutant astrocytoma.

Operations: The business generates about US$170 million from oncology development activities, primarily across the United States, Japan, and China.

Market Cap: US$1.76b

Nuvation Bio fits the Financially Fit Penny Stocks screener because it brings a focused oncology toolkit. It is anchored by late-stage assets that already give investors tangible programs to track rather than just early ideas on a slide deck.

"Advancement of safusidenib into a pivotal Phase III high grade IDH1 mutant glioma maintenance study, targeting a population underserved by existing therapies, could position the company to tap into a durable brain tumor market and add a second meaningful revenue pillar that has the potential to scale earnings beyond IBTROZI."

What happens to Nuvation Bio’s long-run earnings power depends heavily on how one unseen pressure shapes future pricing and reimbursement dynamics.

Those shifting pressures on pricing and reimbursement are exactly what the full narrative for Nuvation Bio unpacks, highlighting where Nuvation Bio’s story could accelerate or stall next.

Grab Holdings (GRAB)

Overview: Grab Holdings runs a Southeast Asian superapp that blends ride-hailing, deliveries, digital payments, and GrabFin lending and banking services.

Operations: Grab generates about US$4.7b in annual revenue, led by Deliveries at US$1,987 million, Mobility at US$1,310 million and Financial Services at US$430 million.

Market Cap: US$13.0b

Grab matters for the Financially Fit Penny Stocks theme because its GrabFin arm layers a lending and digital banking engine on top of an already scaled transport and delivery platform. This gives you fintech exposure inside a broader ecosystem that is not entirely dependent on early-stage credit economics.

"Financial Services may eventually become Grab's second economic engine. Revenue there increased 59%, while the segment's adjusted EBITDA loss narrowed from $26 million to $15 million."

What happens when one still-developing fintech pillar either turns sustainably cash generative or leans harder on higher cost external funding will be crucial.

When that funding balance shifts, the full narrative for Grab Holdings shows whether Grab Holdings' superapp is quietly building a second engine or masking new risk in the background.

Under Armour (UAA)

Overview: Under Armour designs and sells performance-focused athletic apparel, footwear, and accessories across its UNDER ARMOUR and related sportswear brands.

Operations: Under Armour produces most of its roughly US$5b in revenue in North America at US$2.8b, with EMEA and Asia-Pacific contributing over US$1.9b combined.

Market Cap: US$2.1b

For the Financially Fit Penny Stocks theme, Under Armour matters because its core athletic apparel and footwear lines are the cash engines that need to support a cleaner, more resilient earnings profile at a low share price.

"The company is simplifying its product lineup by cutting about 25% of offerings over the next 18 months in order to sell fewer items at full price and reduce reliance on discounting, with a focus on product quality and closer coordination across product, marketing, and sales teams."

What happens to Under Armour’s margins if a single assumption about how much full price demand this leaner assortment can command breaks?

If that full price bet is the real swing factor, the full narrative for Under Armour explains how Under Armour’s reset could shift from stalled to accelerating.

Seeking Alternatives Before Momentum Flies

Fresh ideas move first. Breakout stories and quiet compounders often get caught once momentum is already flying. Scan these under the radar for now opportunities while it matters and act now.

• Spot resilient operators that can carry portfolios through rough patches by scanning a curated 31 resilient stocks with low risk scores before the crowd starts pricing in that resilience.
• Ride structural themes in materials and infrastructure by zeroing in on a hand picked group of 16 top copper producer stocks while attention is still dropping elsewhere.
• Position ahead of potential cash flow inflection by reviewing a tightly filtered mix of 29 high quality undervalued stocks that could rerate once fresh buying momentum appears.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com